MarginsXMarginsX
Home › Markets › Health Care › ELAN

Elanco Animal Health Incorporated (ELAN)

ELAN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$26.41
-1.38% on the day
Market cap
$13.2B
Large cap
Revenue · 2025
$4.7B
+6.2% on 2024
Net income · 2025
-$232.0M
-4.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/0001739104-26-000012-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerELAN on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001739104
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$4.7B
Net income-$232.0M
Operating incomeNot in SEC XBRL data
Net margin-4.9%
Operating marginOperating income not reported
Revenue growth+6.2%
Cash$545.0M
Total assets$13.4B
P/E (computed)Net income was not positive
P/S (computed)2.8×

Warning signs

Cash runway
Cash-flow positive
$465.0M cash at September 30, 2026
Share count, 1 year
+0.6%
2025-10-31 to 2026-11-04 · +1.4% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
$2.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$465.0M cash; operating cash flow $153.5M a quarter.Report 2026-09-30
Shares outstanding499,827,067 (2026-11-04); 496,863,473 a year earlier; 492,798,113 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Indianapolis, Indiana, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2.6M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.3B$18.0M$216.0M$465.0M$3.4B$5.1B10-Q 2026-11-06
Q2 2026
2026-06-30
$1.4B$54.0M$277.0M$530.0M$3.7B$5.0B10-Q 2026-08-05
Q1 2026
2026-03-31
$1.4B$57.0M$13.0M$428.0M$3.7B$4.9B10-Q 2026-05-06
Q4 2025
2025-12-31
$1.1B-$276.0M$108.0M$545.0M$3.8B$4.7B10-K 2026-02-24
Q3 2025
2025-09-30
$1.1B-$34.0M$219.0M$505.0M$3.8B$4.6B10-Q 2026-11-06
Q2 2025
2025-06-30
$1.2B$11.0M$237.0M$539.0M$4.0B$4.5B10-Q 2026-08-05
Q1 2025
2025-03-31
$1.2B$67.0M-$4.0M$487.0M$4.4B$4.4B10-Q 2026-05-06
Q4 2024
2024-12-31
$1.0B-$8.0M$177.0M$468.0M$4.3B$4.4B10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B72020-12-02
Latest annual report
10-K FOR THE YEAR ENDED DECEMBER 31, 2025
10-K2026-02-24
Latest quarterly / interim
10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2026
10-Q2026-11-06
Latest current report
8-K DATED NOVEMBER 6, 2026
8-K2026-11-06
Latest proxyDEFA14A2026-04-08

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.0%
1 month+19.5%
3 months+19.0%
Year to date+18.3%
1 year+21.8%
From 52-week high-0.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RDYDr. Reddy's Laboratories Ltd$14.70-0.27%$12.3B
BBIOBridgeBio Pharma Inc.$77.36-1.20%$15.1B
JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$239.77-0.74%$15.4B
BMRNBioMarin Pharmaceutical Inc.$57.99+1.33%$11.2B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B
ASNDAscendis Pharma A/S Ordinary Share$271.73-1.33%$17.9B
TGTXTG Therapeutics Inc.$62.76-2.71%$9.5B
SMMTSummit Therapeutics Inc. Common Stock$11.82-16.47%$9.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier